Analyst Reco. Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
109.3 ^USD	+2.03%		-3.72%	-11.16%

Apr. 02	Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	MT
Apr. 02	Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating	Mar. 25	MT
Piper Sandler Adjusts Price Target on Jazz Pharmaceuticals to $188 From $171, Maintains Overweight Rating	Mar. 20	MT
Stifel Raises Jazz Pharmaceuticals' Price Target to $230 From $225, Maintains Buy Rating	Mar. 15	MT
H.C. Wainwright Cuts Price Target on Jazz Pharmaceuticals to $200 From $204, Maintains Buy Rating	Mar. 14	MT
UBS Adjusts Jazz Pharmaceuticals Price Target to $131 From $135, Maintains Neutral Rating	Mar. 01	MT
Barclays Cuts Price Target on Jazz Pharmaceuticals to $230 From $235, Maintains Overweight Rating	Mar. 01	MT
Needham Cuts Price Target on Jazz Pharmaceuticals to $220 From $225, Maintains Buy Rating	Feb. 29	MT
Barclays Adjusts Jazz Pharmaceuticals' Price Target to $235 From $240, Keeps Overweight Rating	Jan. 29	MT
RBC Raises Price Target on Jazz Pharmaceuticals to $195 From $191, Keeps Outperform Rating	Jan. 03	MT
Baird Initiates Jazz Pharmaceuticals With Outperform Rating, Price Target is $160	Jan. 03	MT
UBS Downgrades Jazz Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $135 From $170	Nov. 27	MT
Needham Adjusts Jazz Pharmaceuticals' Price Target to $225 From $226, Maintains Buy Rating	Nov. 09	MT
RBC Cuts Price Target on Jazz Pharmaceuticals to $191 From $200, Keeps Outperform Rating	Nov. 09	MT
Raymond James Initiates Jazz Pharmaceuticals With Market Perform Rating	23-09-29	MT
Cantor Fitzgerald Cuts Jazz Pharmaceuticals' Price Target to $180 From $210, Keeps Overweight Rating	23-08-14	MT
Cantor Fitzgerald Cuts Price Target on Jazz Pharmaceuticals to $180 From $210, Maintains Overweight Rating	23-08-14	MT
RBC Trims Price Target on Jazz Pharmaceuticals to $201 From $203, Keeps Outperform Rating	23-08-10	MT
RBC Lifts Jazz Pharmaceuticals' Price Target to $203 From $202, Keeps Outperform Rating	23-07-07	MT
Needham Adjusts Price Target on Jazz Pharmaceuticals to $212 From $205, Maintains Buy Rating	23-05-11	MT
RBC Cuts Price Target on Jazz Pharmaceuticals to $202 From $207, Notes 'Soft' Q1 Revenue Amid Seasonality, Keeps Outperform Rating	23-05-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Analyst Reco.

Filters